Orion Oyj (0M2N.L)
- Globe Newswire
Orion Corporation: Managers’ transactions – Satu Ahomäki
ORION CORPORATIONMANAGERS’ TRANSACTIONS 11 August 2022 at 11.30 EEST Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________ Person subject to the notification requirementName: Satu A
- Globe Newswire
U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
ORION CORPORATION PRESS RELEASE 8 August 2022 at 9:30 EEST U.S. FDA approves additional indication of darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Darolutamide now has indications in both non-metastatic castration-resistant prostate cancer (nmCRPC) for men at high risk of developing metastatic disease and metastatic hormone-sensitive prostate cancer (mHSPC).Approval under the FDA’s Real-Time Oncology Review (RTOR) pilot prog
- Globe Newswire
Orion Corporation: Managers’ transactions – Virve Laitinen
ORION CORPORATION MANAGERS’ TRANSACTIONS 5 August 2022 at 11.15 EEST Orion Corporation: Managers’ transactions – Virve Laitinen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons. Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Virve
